Focal Adhesion Kinase (FAK) tyrosine 397E mutation restores the vascular leakage defect in endothelium‐specific FAK‐kinase dead mice

Focal adhesion kinase (FAK) inhibitors have been developed as potential anticancer agents and are undergoing clinical trials. In vitro activation of the FAK kinase domain triggers autophosphorylation of Y397, Src activation, and subsequent phosphorylation of other FAK tyrosine residues. However, how...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Pathol
Main Authors: Alexopoulou, Annika N, Lees, Delphine M, Bodrug, Natalia, Lechertier, Tanguy, Fernandez, Isabelle, D'Amico, Gabriela, Dukinfield, Matthew, Batista, Silvia, Tavora, Bernardo, Serrels, Bryan, Hodivala‐Dilke, Kairbaan
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2017
Assuntos:
Original Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5518444/
https://ncbi.nlm.nih.gov/pubmed/28444899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/path.4911
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados